{"id":"inotuzumab-ozogamicin-standard-maintenance-therapy","brandName":"Inotuzumab Ozogamicin+Standard Maintenance Therapy","genericName":"inotuzumab-ozogamicin-standard-maintenance-therapy","companyId":"pfizer","companyName":"Pfizer Inc.","phase":"phase_3","status":"active","modality":"Monoclonal antibody","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":5,"visitCount":5,"mechanism":{"target":"CD22","drugClass":"Antibody-drug conjugate","explanation":"Inotuzumab ozogamicin binds to CD22 on cancerous B-cells, releasing a potent toxin that disrupts cellular processes and leads to apoptosis, effectively targeting the CD22 pathway.","oneSentence":"Inotuzumab ozogamicin targets CD22 on B-cell leukemia cells, delivering a cytotoxic agent to induce cell death."},"administration":{},"safety":{},"trials":[],"indications":{"approved":[],"pipeline":[],"offLabel":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:38:12.002588+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}